Actively Recruiting
Pilot Study Evaluating TumorGlow Indocyanine Green for Imaging and Removal of Lung Sarcoma Metastases in Children
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-11-02
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and initial effectiveness of a single dose of indocyanine green ICG, known as TumorGlow, used with near-infrared NIR fluorescent imaging in children aged 12 to 17 with suspected metastatic sarcoma in the lungs. This early-phase study aims to assist surgeons in identifying and removing lung tumors more precisely during surgery. Participants will receive a single intravenous infusion of 5 mgkg of ICG up to five days before their planned lung surgery. During the surgical procedure, standard white light and palpation methods are used first to locate suspicious nodules. Then, NIR fluorescent imaging is applied to help detect lesions that might not be visible otherwise. All identified nodules will be surgically removed, and the surgical field will be re-examined using NIR imaging to ensure complete tumor removal. Participants will be screened up to 60 days before infusion to confirm eligibility. Assessments include monitoring for adverse events over one year following the procedure. The study team will evaluate the number and location of lesions detected by both white light and NIR imaging, margin status of removed tissues, and any fluorescence detected during back-table examination. Safety and sensitivity outcomes related to the use of ICG are tracked for one year after surgery.
CONDITIONS
Brief Title
Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients
Research Team
P
Peter Mattei, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here